The kidneys play a central role in the clearance of rhGH in rats
- PMID: 26946443
- DOI: 10.1016/j.ejps.2016.02.019
The kidneys play a central role in the clearance of rhGH in rats
Abstract
The kidneys are thought to play an important role in the clearance of recombinant human growth hormone (rhGH), but the relative importance is not clear. Obtaining knowledge of clearance pathway is an important prerequisite for the development of new long acting growth hormone analogues targeted at treatment of patients with growth hormone disorders. The purpose of this study was to investigate the relative importance of the kidneys in the clearance of rhGH. The study employed a newly validated nephrectomy rat model and a population based pharmacokinetic approach to assess renal clearance of rhGH in non-anesthetized rats, anesthetized rats and in nephrectomized anesthetized rats. Clearance in non-anesthetized rats was 290 ml/h/kg. This was reduced to 185 ml/h/kg by anesthesia and further reduced to 18 ml/h/kg by nephrectomy. As nephrectomy was able to reduce clearance with 90%, we conclude that renal clearance plays a pivotal role in the elimination of rhGH in rats.
Keywords: Clearance; Kidney; Nephrectomy; Non-linear mixed effect modeling; Pharmacokinetics; rhGH.
Copyright © 2016 Elsevier B.V. All rights reserved.
Similar articles
-
Establishment and use of surgical rat models for assessment of organ specific in vivo clearance.Dan Med J. 2016 Jun;63(6):B5247. Dan Med J. 2016. PMID: 27264946 Review.
-
The kidneys play an important role in the clearance of rFVIIa in rats.Thromb Res. 2014 Jun;133(6):1124-9. doi: 10.1016/j.thromres.2014.03.034. Epub 2014 Mar 25. Thromb Res. 2014. PMID: 24731563
-
Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.Mol Pharm. 2015 Oct 5;12(10):3759-65. doi: 10.1021/acs.molpharmaceut.5b00550. Epub 2015 Sep 21. Mol Pharm. 2015. PMID: 26370910
-
[Pharmacokinetics of rhGH decorated by polyethylene glycol in rat in vivo].Yao Xue Xue Bao. 2009 May;44(5):506-9. Yao Xue Xue Bao. 2009. PMID: 19618727 Chinese.
-
Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.Expert Opin Biol Ther. 2013 Jun;13(6):927-32. doi: 10.1517/14712598.2013.795941. Expert Opin Biol Ther. 2013. PMID: 23662811 Review.
Cited by
-
Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):573-581. doi: 10.1007/s13318-016-0371-0. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27535556
-
Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.Clin Pharmacokinet. 2019 Jan;58(1):63-75. doi: 10.1007/s40262-018-0662-5. Clin Pharmacokinet. 2019. PMID: 29671202 Free PMC article. Clinical Trial.
-
Growth Hormone Dosing Estimations Based on Body Weight Versus Body Surface Area.J Clin Res Pediatr Endocrinol. 2023 Aug 23;15(3):268-275. doi: 10.4274/jcrpe.galenos.2023.2022-12-18. Epub 2023 Mar 28. J Clin Res Pediatr Endocrinol. 2023. PMID: 36974729 Free PMC article.
-
Tissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative.Int J Mol Sci. 2020 Feb 11;21(4):1181. doi: 10.3390/ijms21041181. Int J Mol Sci. 2020. PMID: 32053994 Free PMC article.
-
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.J Clin Endocrinol Metab. 2021 Jan 23;106(2):567-576. doi: 10.1210/clinem/dgaa775. J Clin Endocrinol Metab. 2021. PMID: 33313798 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials